权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies on Antiviral Immunity-Assisted Cancer Immunotherapy

抗病毒免疫辅助癌症免疫治疗的研究

基本信息

批准号：
08556048
负责人：
KYUWA Shigeru
金额：
$ 2.56万
依托单位：
The University of Tokyo
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
1996
资助国家：
日本
起止时间：
1996 至 1997
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08556048/
关键词：
cancer virus CTL tumor immunology mouse hepatitis virus immunotherapy melanoma vaccine 細胞傷害性T細胞(CTL)

项目摘要

We attempted to examine whether or not antiviral cytotoxic T lymphocytes (CTL)-induced cytolysis of tumor cells expressing viral CTL epitope could enhance antitumor immunity in an experimental model. We used B16 murine melanoma derived from C57BL/6 (B6) mouse and murine coronavirus infection in our model. Groups of B6 mice were immunized with murine coronavirus, strain JHM (JHMV). Four weeks later, they were injected subcataneously with 2*10^6 melanoma cells. Two weeks later, infectious JHMV,JHMV-derived antigenic peptides or PBS was injected into the tumors in each group. However, there was no difference in the survival time of mice. In the second experiment, B6 mice immunized with JHMV or naive ones were vaccinated twice with irradiated B16 melanoma cells either infected with JHMV,pulsed with JHMV-derived antigenic peptides or incubated in PBS (control). Then, they were challenged with the same tumor intravenously and monitored their survival. The survival time of naive mice receirved with irradiated B16 melanoma cells infected with JHMV was significantly longer than that of control mice, although the same anticancer vaccine did not elongate the survival time of JHMV-immunized mice. JHMV-immunized mice received with irradiated B16 melanoma cells pulsed with viral peptide died as quickly as control mice. These results suggest that anti-B16 melanoma immune response is not augmented by anti-JHMV CTL response in B6 mice. However, it is necessary to test further with other tumors.

我们试图检查是否抗病毒的细胞毒性T淋巴细胞（CTL）诱导的细胞溶解表达病毒CTL表位的肿瘤细胞可以增强抗肿瘤免疫的实验模型。我们在我们的模型中使用来自C57 BL/6（B6）小鼠和鼠冠状病毒感染的B16鼠黑素瘤。用鼠冠状病毒株JHM（JHMV）免疫B6小鼠组。四周后，他们被皮下注射2*10^6个黑色素瘤细胞。两周后，将感染性JHMV、JHMV衍生的抗原肽或PBS注射到各组的肿瘤中。但是，小鼠的存活时间没有差异。在第二个实验中，用JHMV免疫的B6小鼠或未处理的B6小鼠用照射的B16黑素瘤细胞接种两次，所述B16黑素瘤细胞用JHMV感染、用JHMV衍生的抗原肽脉冲或在PBS中孵育（对照）。然后，他们通过静脉注射相同的肿瘤，并监测他们的生存情况。用辐照过的B16黑色素瘤细胞感染JHMV的小鼠的存活时间明显长于对照小鼠，但同一种抗癌疫苗并不能延长JHMV免疫小鼠的存活时间。JHMV免疫的小鼠接受用病毒肽脉冲的辐照B16黑素瘤细胞后与对照小鼠一样迅速死亡。这些结果表明，在B6小鼠中，抗JHMV CTL应答不增强抗B16黑素瘤免疫应答。但是，有必要进一步用其他肿瘤进行测试。